Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS7 | Q9UKP4 | 19/20 | 0.69 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31676828 | 1.00 | ADAMTS7 (0.69) | ADAMTS7MMP2ADAMTS5 | |
| SCHEMBL23354327 | 0.86 | ADAMTS7 (0.77) | ADAMTS7MMP2ADAMTS5 | |
| SCHEMBL29978922 | 0.86 | ADAMTS7 (0.77) | ADAMTS7MMP2ADAMTS5 | |
| SCHEMBL23354210 | 0.86 | ADAMTS7 (0.79) | ADAMTS7MMP2ADAMTS5 | |
| SCHEMBL23366974 | 0.85 | ADAMTS7 (0.78) | ADAMTS7MMP2ADAMTS5 | |
| SCHEMBL29979764 | 0.84 | ADAMTS7 (0.71) | ADAMTS7MMP2ADAMTS5 | |
| SCHEMBL23367005 | 0.84 | ADAMTS7 (0.71) | ADAMTS7MMP2ADAMTS5 | |
| SCHEMBL23354246 | 0.84 | ADAMTS7 (0.74) | ADAMTS7MMP2ADAMTS5 | |
| SCHEMBL23354099 | 0.84 | ADAMTS7 (0.80) | ADAMTS7MMP2ADAMTS5 | |
| SCHEMBL23354168 | 0.84 | ADAMTS7 (0.77) | ADAMTS7MMP2ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4058448-B1 | HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-4058448-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021094436-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021094436-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3822268-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-3822268-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2021-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAM17 | ADAMTS7 1/4885MMP2 137/4885ADAMTS5 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.